

HDFC Life Insurance

| ↓ |
|-------------------|
| \longrightarrow |
| \longrightarrow |
| |

| Bloomberg | HDFCLIFE IN |
|-----------------------|---------------|
| Equity Shares (m) | 2156 |
| M.Cap.(INRb)/(USDb) | 1641.1 / 18.6 |
| 52-Week Range (INR) | 821 / 584 |
| 1, 6, 12 Rel. Per (%) | -3/-1/6 |
| 12M Avg Val (INR M) | 2211 |

Financials & Valuations (INR b)

| Y/E March | 2025 | 2026E | 2027E |
|-------------------|-------|--------------|-------|
| Net Premiums | 696.2 | 807.4 | 934.3 |
| PBT | 18.7 | 18.1 | 21.5 |
| Surplus / Deficit | 10.4 | 8.4 | 10.3 |
| Sh. PAT | 18.0 | 18.1 | 21.5 |
| NBP gr - APE (%) | 15.8 | 14.4 | 16.7 |
| Premium gr (%) | 12.6 | 16.0 | 15.7 |
| VNB margin (%) | 25.6 | 24.3 | 26.0 |
| RoEV (%) | 16.8 | 15.4 | 16.5 |
| Total AUMs (INRt) | 3.4 | 4.1 | 4.8 |
| VNB (INRb) | 39.6 | 43.0 | 53.7 |
| EV per share | 257.6 | 297.3 | 346.5 |
| Valuations | | | |
| P/EV (x) | 3.0 | 2.6 | 2.2 |
| P/EVOP (x) | 20.7 | 19.0 | 15.4 |

Shareholding pattern (%)

| | | • | |
|----------|--------|--------|--------|
| As On | Jun-25 | Mar-25 | Jun-24 |
| Promoter | 50.3 | 50.3 | 50.4 |
| DII | 14.6 | 14.1 | 11.3 |
| FII | 24.8 | 25.0 | 26.7 |
| Others | 10.4 | 10.6 | 11.7 |

FII includes depository receipts

CMP: INR761 TP: INR910 (+20%) Buy

Performance in line; a 0.5% impact of GST on VNB margin

- HDFC Life Insurance (HDFCLIFE) reported an APE of INR41.9b (in line) in 2QFY26, up 9% YoY. This was led by a 9%/7% YoY growth in individual/ group APE. For 1HFY26, APE grew 10% YoY to INR74.1b.
- HDFCLIFE's VNB grew 8% YoY to INR10.1b in 2QFY26 (in line), resulting in a VNB margin of 24.1% (vs. our estimate of 24%). For 1HFY26, VNB grew 10% YoY to INR18.2b, leading to a VNB margin of 24.5% (flat YoY).
- For 2QFY26, HDFCLIFE reported a 3% YoY growth in shareholders' PAT to INR4.5b (6% miss), supported by a 14% increase in back-book profits. For 1HFY26, its PAT grew 9% YoY to INR9.9b while EV at the end of 1HFY26 was at INR595.4b (RoEV of 14.2%).
- Going forward, management expects mid-teens growth, which should be better than the industry. VNB growth should normalize from FY27, supported by operational adjustments and distribution realignments over the next 2-3 quarters to mitigate the loss of input tax credit. The expectation is to end 4QFY26 with a stable VNB margin.
- We trim our VNB margin assumptions by 70bp for FY26, considering the impact of the loss of input tax credit. We have factored in a 0.5% EV hit on the back book, leading to a 0.6% decline in our FY26/FY27/FY28 EV estimates. We roll over to Sep'27E EV to arrive at our TP of INR910 (based on 2.4x Sep'27E EV). Reiterate BUY.

Improving trends in the protection segment

- For 2Q, HDFCLIFE posted a 14% YoY growth in gross premium to INR192.9b (in line), led by 17%/11% YoY growth in renewal/single premium.
- Overall APE growth of 9% YoY was driven by an 82%/44%/20% YoY growth in Par/ULIP/Term business, while non-par and group business reported a YoY decline of 53%/10%. Individual APE witnessed a YoY increase in contribution from ULIP/Par/Term to 45%/27%/8%.
- The share of ULIPs in total APE increased to 40%, reflecting the rising demand for ULIPs. However, the gradual shift towards higher sum assured ULIPs with rider attachments has helped in maintaining the VNB margin despite rising ULIP contributions.
- The share of the par segment increased to 24% from 14% in 2QFY25 on account of new product offerings. The share of the non-par segment dipped to 15% (35% in 2QFY25) but is expected to improve going forward, with attractiveness increasing owing to declining interest rates and rising demand for guaranteed solutions.
- The protection segment is experiencing traction as the share of total APE has grown from 12% in 2QFY25 to 13% in 2QFY26. In terms of new business premium, the share of term has increased to 28.2% from 26.6% in 2QFY25. The segment witnessed ~3x growth compared to overall company growth, contributing positively to VNB margin. Retail protection grew 50% post-GST exemption from 22nd Sep'25.



- On an individual APE basis, the banca/agency/direct channels witnessed a YoY growth of 12%/25%/19%. HDFC's counter share remained stable, while wallet share among other banks is improving compared to 1QFY26, according to the management.
- HDFCLIFE's persistency ratios have declined YoY across all cohorts except 49thmonth persistency, which improved to 70.1% from 69.2% in 2QFY25.
- As of Sep'25, total AUM increased by 11% YoY to INR3.6t.
- Embedded Value (EV) grew 14.2% YoY to INR595.4b as of Sep'25, with operating RoEV for 1HFY26 at 15.8%. The solvency ratio for the quarter stood at 175% and is expected to improve to 180-185% post-debt raising in 2HFY26.
- HDFCLIFE's commission ratios have seen an increase YoY to 12% (10.9% in 2QFY25), offset by operational efficiencies, resulting in a rise in overall expense ratio to 21.3% from 20.9% in 2QFY25.

Highlights from the management commentary

- Around 80% of September's new business was issued post-GST changes, showing early signs of stronger growth post-GST changes.
- HDFCLIFE plans to raise INR7.5b of debt in 2HFY26, which is expected to enhance solvency by around 7%. Solvency levels dipped due to 1) dividend payout 4.5%, 2) subordinated debt repayment 6%, 3) GST impact 1.5%, and 4) new business strain. Management aims to maintain solvency within the 180–185% range.
- About 50% of the input tax credit loss arises from distributor commissions, with the remainder stemming from technology and outsourcing expenses.
 Management is actively engaging with vendors and distributors to share costs and optimize efficiency.

Valuation and view

- HDFCLIFE maintains an industry-leading growth trajectory along with a stable VNB margin driven by a diversified product mix, rising sum assured (especially in ULIPs), and improving rider attachments. While the impact of input tax credit loss will dampen the profitability in the short run, a strong growth trajectory, improving product-level margin, and cost optimization measures should help normalize its VNB margin.
- We trim our VNB margin assumptions by 70bp for FY26, considering the impact of the loss of input tax credit. We have factored in a 0.5% EV hit on the back book, resulting in a 0.6% decline in our FY26/27/28 EV estimates. We roll over to Sep'27E EV to arrive at our TP of INR910 (based on 2.4x Sep'27E EV). Reiterate BUY.

15 October 2025



Quarterly performance

| Policyholdoric A /c /INP h) | | FY | 25 | | | FY2 | 26 | | FY25 FY26 | EVACE | FY26E | V/s | YoY (%) | QoQ |
|-----------------------------|-------|-------|--------|-------|-------|--------|--------|-------|------------|-------|-------|--------|---------|--------|
| Policyholder's A/c (INR b) | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3QE | 4QE | F125 | F120E | 2Q | est | 101 (%) | (%) |
| First-year premium | 23.6 | 32.5 | 29.7 | 44.0 | 25.5 | 35.8 | 34.9 | 52.2 | 129.8 | 148.3 | 36.0 | -0.7 | 10.0 | 40.4 |
| Growth (%) | 27.4 | 26.8 | 10.8 | 9.5 | 8.2 | 10.0 | 17.4 | 18.7 | 16.8 | 14.3 | 10.8 | | | |
| Renewal premium | 64.1 | 88.3 | 93.8 | 130.6 | 76.0 | 103.4 | 110.3 | 151.4 | 376.8 | 441.1 | 101.4 | 1.9 | 17.1 | 36.0 |
| Growth (%) | 10.5 | 12.7 | 11.7 | 14.5 | 18.6 | 17.1 | 17.6 | 15.9 | 12.7 | 17.1 | 14.9 | | | |
| Single premium | 40.4 | 48.4 | 49.3 | 65.7 | 47.2 | 53.7 | 56.3 | 77.4 | 203.9 | 234.6 | 54.0 | -0.5 | 10.9 | 13.7 |
| Growth (%) | 0.6 | 6.8 | 10.8 | 19.1 | 16.8 | 10.9 | 14.2 | 17.7 | 10.1 | 15.1 | 11.4 | | | |
| Gross premium inc. | 128.1 | 169.3 | 172.8 | 240.3 | 148.8 | 192.9 | 201.4 | 281.0 | 710.4 | 824.0 | 191.5 | 0.7 | 13.9 | 29.7 |
| Growth (%) | 9.7 | 13.3 | 11.3 | 14.8 | 16.1 | 13.9 | 16.6 | 16.9 | 12.6 | 16.0 | 13.1 | | | |
| Surplus/(Deficit) | 5.6 | 5.1 | -1.9 | 1.6 | 0.8 | -1.7 | 4.2 | 5.1 | 10.4 | 8.4 | 2.6 | -165.1 | -133.7 | -306.4 |
| Growth (%) | 165.7 | 122.6 | -415.7 | -40.1 | -85.2 | -133.7 | -317.7 | 212.3 | <i>3</i> 5 | -19.2 | -48 | | | |
| PAT | 4.8 | 4.3 | 4.1 | 4.8 | 5.5 | 4.5 | 3.6 | 4.5 | 18.0 | 18.1 | 4.8 | -5.9 | 3.3 | -18.2 |
| Growth (%) | 15.0 | 14.9 | 13.7 | 15.9 | 14.4 | 3.3 | -12.9 | -5.3 | 14.9 | 0.2 | 9.7 | | | |
| Key metrics (INRb) | | | | | | | | | | | | | | |
| New business APE | 28.7 | 38.6 | 35.7 | 51.9 | 32.3 | 41.9 | 41.7 | 61.3 | 154.8 | 177.1 | 42.7 | -1.9 | 8.6 | 29.9 |
| Growth (%) | 23.1 | 26.7 | 11.8 | 9.7 | 12.5 | 8.6 | 16.8 | 18.1 | 16.5 | 14.4 | 10.6 | | | |
| VNB | 7.2 | 9.4 | 9.3 | 13.8 | 8.1 | 10.1 | 9.8 | 15.0 | 39.6 | 43.0 | 10.2 | -1.3 | 7.8 | 25.0 |
| Growth (%) | 17.7 | 17.1 | 8.6 | 11.5 | 12.7 | 7.8 | 5.4 | 9.3 | 13.2 | 8.6 | 9.2 | | | |
| AUM (INR b) | 3,102 | 3,249 | 3,287 | 3,363 | 3,559 | 3,600 | 3,816 | 4,062 | 3,363 | 4,062 | 3,773 | -4.6 | 10.8 | 1.2 |
| Growth (%) | 22.5 | 22.7 | 17.5 | 15.1 | 14.7 | 10.8 | 16.1 | 20.8 | 15.1 | 20.8 | 16.1 | | | |
| Key Ratios (%) | | | | | | | | | | | | | | |
| VNB Margins (%) | 25.0 | 24.3 | 26.1 | 26.5 | 25.1 | 24.1 | 23.5 | 24.5 | 25.6 | 24.3 | 24.0 | 14bp | -17bp | -96bp |

Exhibit 1: Our revised estimates

| | N | ew Estimat | es | Old Estimates | | | Change in Estimates (%) | | |
|--------------------------|-------|------------|---------|---------------|-------|---------|-------------------------|-------|-------|
| Y/E MARCH | FY26E | FY27E | FY28E | FY26E | FY27E | FY28E | FY26E | FY27E | FY28E |
| Net Premiums (INRb) | 807.4 | 934.3 | 1,081.9 | 807.4 | 934.3 | 1,081.9 | - | - | - |
| PBT (INRb) | 18.1 | 21.5 | 24.6 | 20.2 | 22.6 | 25.9 | | | |
| Surplus / Deficit (INRb) | 8.4 | 10.3 | 11.6 | 10.6 | 11.4 | 12.8 | -20.4 | -10.2 | -10.0 |
| Sh. PAT (INRb) | 18.1 | 21.5 | 24.6 | 20.2 | 22.6 | 25.9 | -10.7 | -5.1 | -4.9 |
| NBP gr - APE (%) | 14.4 | 16.7 | 16.7 | 14.4 | 16.7 | 16.7 | | | |
| Premium gr (%) | 16.0 | 15.7 | 15.8 | 16.0 | 15.7 | 15.8 | | | |
| VNB margin (%) | 24.3 | 26.0 | 26.5 | 25.0 | 26.0 | 26.5 | -0.7 | - | - |
| RoEV (%) | 15.4 | 16.5 | 16.7 | 16.1 | 16.5 | 16.7 | | | |
| Total AUMs (INRt) | 4.1 | 4.8 | 5.6 | 4.1 | 4.8 | 5.6 | | | |
| VNB (INRb) | 43.0 | 53.7 | 63.9 | 44.3 | 53.7 | 63.9 | -2.8 | - | - |
| EV per share | 297.3 | 346.5 | 404.4 | 299 | 349 | 407 | -0.6 | -0.6 | -0.5 |





Highlights from the management commentary

Business performance

- HDFC Life outperformed both the overall industry and private peers, leading to an increase in overall market share to 11.9% and 16.6% within the private sector for 1HFY26. Going forward, the company expects mid-teens growth, which should be better than the industry.
- Notably, 70% of new customers in 1HFY26 were first-time buyers, indicating strong franchise expansion and penetration gains.
- Around 80% of September's new business was issued post-GST changes, showing early signs of stronger growth post-GST changes.
- HDFCLIFE plans to raise INR7.5b of debt in 2HFY26, which is expected to enhance solvency by around 7%. Solvency levels dipped due to 1) dividend payout 4.5%,
 2) subordinated debt repayment 6%, 3) GST impact 1.5%, and 4) new business strain. Management aims to maintain solvency within the 180–185% range.
- HDFC Pension retained leadership with a 43% market share, delivering 30% YoY growth.
- Tier-2/3 cities continue to form a strong growth engine, contributing ~70% of new business, and this mix is expected to remain steady.

VNB margin and product mix

- Before accounting for GST, VNB margin stood at 25%, which moderated slightly to 24.5% including the GST impact.
- Management expects normalized VNB growth from FY27, supported by operational adjustments and distribution realignments over the next 2–3 quarters to mitigate the loss of input tax credit. The expectation is to end 4QFY26 with a stable VNB margin.
- The company aims to improve product-level margins by increasing the share of high-sum-assured and high-margin ULIP products, offsetting the GST-related impact over time.
- The protection business surged 3x the company's overall growth, contributing positively to margins. Annuities grew 16% YoY, maintaining strong momentum.
- Higher sum assured in ULIPs and rider attachment options helped sustain margin levels despite the rising ULIP and Par share.
- ULIPs continued to witness strong inflows, aided by buoyant equity markets and sustained demand for market-linked returns.
- Demand for non-par savings picked up and is expected to accelerate further, supported by yield curve movements and customer preference for guaranteed solutions. Pricing was aggressive in the past, but the company expects rationalization going ahead.
- Retail protection growth outpaced the overall business, with early signs of improved traction post-GST. Individual retail term premiums grew over 50% after GST implementation, while credit protect saw a rebound in September.
- The variable annuity product is in the discussion stage with the regulator and expected to launch by 4QFY26.



Channel mix:

- HDFC Life's counter share with HDFC Bank remained stable, while other bancassurance partnerships expanded, broadening its distribution footprint. The growth for banks beyond HDFC Bank was lower in 1HFY26 due to lower wallet share in 1Q, post which there has been improvement.
- The broker channel growth is driven by protection products and increased wallet share among key brokers. The broking channel now contributed 9% of APE, and management expects this contribution to remain steady in the near term.


GST reforms:

- The company has passed on the full benefit of the GST exemption to customers, improving product affordability and stimulating demand.
- The loss of input tax credit will exert short-term margin pressure, but management is confident of offsetting this impact through cost optimization, vendor discussions, and distributor negotiations within the next 2–3 quarters.
- About 50% of the input tax credit loss arises from distributor commissions, with the remainder stemming from technology and outsourcing expenses.
 Management is actively engaging with vendors and distributors to share costs and optimize efficiency.
- The biggest impact of input tax credit loss is on ULIP because of the cap on charges. HDFC Life witnessed a 0.5% impact on VNB in 2QFY26 and expects 3% impact on gross basis for the full year.
- Despite 2H being seasonally stronger, management expects some lag in recovery as the input tax credit loss is gradually absorbed. Nevertheless, increased growth momentum, product innovation, and calibrated margin levers are expected to drive VNB normalization from FY27.




Key exhibits

Exhibit 2: Share of term improved YoY to 8% of individual APE




Source: MOFSL, Company

Exhibit 3: Share of ULIP/Par/Non-par/Term at 40%/23%/ 15%/13% of total APE




Source: MOFSL, Company

Exhibit 4: Improving trends in the 61st persistency ratio




Source: MOFSL, Company

Exhibit 5: Distribution mix for individual APE




Source: MOFSL, Company

Exhibit 6: Operating RoEV healthy at 16%



Source: MOFSL, Company

Exhibit 7: VNB margin at 24.1% for 2QFY26




Source: MOFSL, Company



Exhibit 8: Net premium income grew 13.3% YoY

Exhibit 9: Proportion of premium trends among first-year, single, and renewal premiums





| | Firs | t ye | ar pr | emiu | ım | ■ R | enev | val p | remi | um | ■ S | ingle | pre | mium |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 3 | 33 | 30 | 32 | 30 | 35 | 31 | 29 | 27 | 32 | 29 | 29 | 28 | 33 | 29 |
| į | 52 | 53 | 50 | 48 | 51 | 53 | 55 | 56 | 51 | 53 | 56 | 55 | 53 | 55 |
| | 17 | 18 | 19 | 23 | 16 | 17 | 18 | 20 | 19 | 20 | 18 | 18 | 18 | 19 |
| í | 1QFY23 | 2QFY23 | 3QFY23 | 4QFY23 | 1QFY24 | 2QFY24 | 3QFY24 | 4QFY24 | 1QFY25 | 2QFY25 | 3QFY25 | 4QFY25 | 1QFY26 | 2QFY26 |

Source: MOFSL, Company

Exhibit 10: Trend in underwriting profit and shareholders' surplus

Exhibit 11: Solvency ratio stood at 175% in 2QFY26






Source: MOFSL, Company

Source: MOFSL, Company

Exhibit 12: One-year forward P/EV



Source: MOFSL



Financials and valuations

| Technical account (INRm) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E | FY28E |
|-------------------------------|-----------|-----------|-----------|-----------|---|-----------|-----------|-----------|
| Gross Premiums | 3,85,835 | 4,59,628 | 5,75,334 | 6,30,765 | 7,10,449 | 8,24,014 | 9,53,444 | 11,04,149 |
| Reinsurance Ceded | (4,612) | (5,664) | (7,694) | (11,173) | (14,288) | (16,572) | (19,175) | (22,205) |
| Net Premiums | 3,81,223 | | | | | | | |
| Income from Investments | | 4,53,964 | 5,67,640 | 6,19,592 | 6,96,161 | 8,07,442 | 9,34,270 | 10,81,943 |
| | 3,26,776 | 1,92,160 | 1,25,975 | 3,83,543 | 2,59,453 | 3,39,560 | 3,63,241 | 4,21,960 |
| Other Income | 4,420 | 7,460 | 13,439 | 4,608 | 3,834 | 4,218 | 4,639 | 5,103 |
| Total income (A) | 7,12,418 | 6,53,584 | 7,07,054 | 10,07,743 | 9,59,448 | 11,51,220 | 13,02,151 | 15,09,006 |
| Commission | 17104 | 19403 | 28869 | 52563 | 78353 | 89833 | 104703 | 122057 |
| Operating expenses | 45,860 | 56,125 | 84,374 | 69,010 | 62,218 | 69,684 | 76,652 | 84,318 |
| Total commission and opex | 62,964 | 75,528 | 1,13,242 | 1,21,574 | 1,40,571 | 1,59,517 | 1,81,355 | 2,06,375 |
| Benefits Paid (Net) | 2,25,748 | 3,18,637 | 3,88,723 | 3,96,965 | 3,93,459 | 4,65,570 | 5,46,114 | 6,40,428 |
| Chg in reserves | 4,08,296 | 2,46,815 | 1,85,862 | 4,84,194 | 4,15,156 | 5,09,543 | 5,54,811 | 6,39,461 |
| Prov for doubtful debts | 1,682 | 1,162 | 4,047 | 3,183 | 5,715 | 6,678 | 7,808 | 9,134 |
| Total expenses (B) | 6,98,690 | 6,42,142 | 6,91,875 | 10,05,915 | 9,54,901 | 11,41,308 | 12,90,089 | 14,95,398 |
| (A) - (B) | 13,729 | 11,442 | 15,180 | 1,828 | 4,547 | 9,912 | 12,061 | 13,608 |
| Provn for tax | 2,744 | 1,845 | 1,591 | -5,924 | -5,882 | 1,487 | 1,809 | 2,041 |
| Surplus / Deficit | 10,985 | 9,597 | 13,589 | 7,752 | 10,429 | 8,425 | 10,252 | 11,567 |
| Shareholder's a/c (INRm) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E | FY28E |
| Transfer from technical a/c | 9,909 | 10,093 | 14,689 | 7,991 | 9,968 | 8,425 | 10,252 | 11,567 |
| Income From Investments | 6,476 | 7,894 | 7,197 | 10,022 | 11,251 | 12,452 | 14,320 | 16,468 |
| Total Income | 16,385 | 17,987 | 22,519 | 18,144 | 21,220 | 20,879 | 24,574 | 28,037 |
| Other expenses | 637 | 825 | 1,246 | 1,209 | 1,429 | 1,572 | 1,730 | 1,903 |
| Contribution to technical a/c | 2,586 | 5,694 | 8,795 | 1,251 | 1,004 | 1,105 | 1,215 | 1,336 |
| Total Expenses | 2,850 | 6,186 | 9,794 | 2,505 | 2,559 | 2,815 | 3,097 | 3,406 |
| PBT | 13,535 | 11,801 | 12,724 | 15,639 | 18,661 | 18,063 | 21,477 | 24,630 |
| Prov for Tax | 66 | 275 | 877 | 50 | (640) | - | | 24,030 |
| PAT | 13,601 | 12,077 | 13,601 | 15,689 | 18,021 | 18,063 | 21,477 | 24,630 |
| Growth | 5% | -11% | 13% | 15% | 15% | 0% | 19% | 15% |
| - Clowdii | 370 | 11/0 | 1370 | 1370 | 13/0 | <u> </u> | 1370 | 13/0 |
| Balance sheet (INRm) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E | FY28E |
| Sources of Fund | | | | | | | | |
| Share Capital | 20,229 | 21,159 | 21,526 | 21,509 | 21,536 | 21,536 | 21,536 | 21,536 |
| Reserves And Surplus | 64,074 | 1,32,852 | 1,08,146 | 1,20,503 | 1,35,260 | 1,57,633 | 1,83,419 | 2,12,359 |
| Shareholders' Fund | 86,377 | 1,54,859 | 1,29,868 | 1,46,517 | 1,61,256 | 1,83,629 | 2,09,415 | 2,38,355 |
| Policy Liabilities | 8,55,230 | 10,43,425 | 14,32,696 | 17,53,488 | 21,07,778 | 25,26,900 | 30,04,143 | 35,66,880 |
| Prov. for Linked Liab. | 7,09,635 | 7,65,190 | 7,53,836 | 9,21,145 | 9,77,434 | 12,33,557 | 13,99,206 | 15,94,777 |
| Funds For Future App. | 47,866 | 50,435 | 50,533 | 46,386 | 51,424 | 56,567 | 62,223 | 68,446 |
| Current liabilities & prov. | 65,159 | 62,287 | 83,030 | 87,777 | 95,992 | 1,05,591 | 1,16,150 | 1,27,765 |
| Total | 17,95,817 | 21,03,892 | 24,79,222 | 30,25,071 | 34,91,333 | 40,84,708 | 47,69,601 | 55,74,686 |
| Application of Funds | ,,- | , , | , -, | , -,- | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | ,,. | |
| Shareholders' inv | 85,421 | 1,52,379 | 1,31,319 | 1,48,819 | 1,83,863 | 2,11,443 | 2,43,159 | 2,79,633 |
| Policyholders' inv | 9,05,378 | 10,83,110 | 14,64,485 | 18,17,966 | 21,62,671 | 25,93,960 | 30,96,758 | 36,97,235 |
| Assets to cover linked liab. | 7,47,595 | 8,06,215 | 7,92,015 | 9,55,416 | 10,16,282 | 11,38,235 | 12,74,823 | 14,27,802 |
| Loans | 4,240 | 6,428 | 15,853 | 18,972 | 23,783 | 26,161 | 28,777 | 31,655 |
| Fixed Assets | 3,401 | 3,427 | 3,802 | 4,158 | 6,011 | 6,311 | 6,627 | 6,958 |
| Current assets | ٥, .٠٠ | ٥, ٠=, | 0,002 | .,_55 | 0,0_1 | 0,0_1 | 0,0- | 0,000 |
| Current assets | 49,781 | 52,333 | 71,748 | 79,739 | 98,724 | 1,08,597 | 1,19,457 | 1,31,402 |



Financials and valuations

| Operating ratios (%) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E | FY28E |
|------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|
| Investment yield | 22.8% | 10.8% | 6.1% | 15.2% | 8.8% | 9.9% | 9.0% | 8.9% |
| Commissions / GWP | 4.4% | 4.2% | 5.0% | 8.3% | 11.0% | 10.9% | 11.0% | 11.1% |
| - first year premiums | 18.5% | 17.0% | 17.9% | 28.4% | 45.2% | 45.2% | 45.2% | 45.2% |
| - renewal premiums | 1.5% | 1.5% | 1.8% | 1.6% | 1.6% | 1.6% | 1.6% | 1.6% |
| - single premiums | 1.0% | 1.3% | 1.6% | 8.5% | 6.8% | 6.8% | 6.8% | 6.8% |
| Operating expenses / GWP | 11.9% | 12.2% | 14.7% | 10.9% | 8.8% | 8.5% | 8.0% | 7.6% |
| Total expense ratio | 17.6% | 16.3% | 16.4% | 19.7% | 19.3% | 19.8% | 19.4% | 19.0% |
| Claims / NWP | 59.2% | 70.2% | 68.5% | 64.1% | 56.5% | 57.7% | 58.5% | 59.2% |
| Solvency ratio | 201% | 176% | 203% | 187% | 194% | 189% | 184% | 180% |
| Persistency ratios (%) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E | FY28E |
| 13th Month | 90.0% | 87.5% | 87.5% | 87.1% | 86.9% | 86.8% | 86.8% | 86.8% |
| 25th Month | 81.0% | 78.8% | 78.7% | 79.2% | 78.1% | 78.0% | 77.9% | 77.9% |
| 37th Month | 71.0% | 67.5% | 72.4% | 73.2% | 73.6% | 73.3% | 73.2% | 73.2% |
| 49th Month | 67.0% | 63.2% | 64.0% | 69.7% | 70.2% | 71.2% | 71.8% | 72.6% |
| 61st Month | 53.0% | 54.0% | 52.3% | 53.5% | 63.5% | 64.2% | 65.2% | 66.0% |
| Des (1) - 1:11 (0/) | EV24 | EVOO | EVOO | EV2.4 | EVOE | EVACE | EVOZE | EVANE |
| Profitability ratios (%) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E | FY28E |
| VNB margin (%) | 26.1% | 27.4% | 27.5% | 26.3% | 25.6% | 24.3% | 26.0% | 26.5% |
| RoE (%) | 17.6% | 10.0% | 9.6% | 11.4% | 11.7% | 10.5% | 10.9% | 11.0% |
| RoIC (%) | 56.7% | 21.6% | 14.1% | 14.7% | 16.9% | 16.9% | 20.1% | 23.1% |
| Operating ROEV (%) | 18.5% | 16.5% | 19.7% | 17.5% | 16.7% | 15.5% | 16.7% | 16.8% |
| RoEV (%) | 28.9% | 12.9% | 31.5% | 20.1% | 16.7% | 15.4% | 16.5% | 16.7% |
| Valuation data points | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E | FY28E |
| Total AUMs (INRb) | 1,738 | 2,042 | 2,388 | 2,922 | 3,363 | 4,062 | 4,753 | 5,567 |
| DPS | 2.02 | 1.70 | 1.90 | 2.00 | 2.10 | 2.00 | 2.00 | 2.00 |
| Dividend payout ratio (%) | 0% | 33.82 | 26.41 | 26.03 | -0.00 | 23.8 | 20.0 | 17.5 |
| EPS, INR | 6.3 | 5.6 | 6.3 | 7.3 | 8.4 | 8.4 | 10.0 | 11.5 |
| Value of new business (INRb) | 21.9 | 26.7 | 36.7 | 35.0 | 39.6 | 43.0 | 53.7 | 63.9 |
| Embedded Value (INRb) | 266.2 | 329.4 | 395.1 | 474.5 | 554.1 | 639.5 | 745.3 | 869.8 |
| EV per share (INR) | 123.7 | 153.1 | 183.7 | 220.6 | 257.6 | 297.3 | 346.5 | 404.4 |
| VIF as % of EV | 66% | 64% | 68% | 69% | 71% | 72% | 74% | 75% |
| P/VIF (x) | 0.9 | 0.8 | 0.6 | 0.5 | 0.4 | 0.4 | 0.3 | 0.2 |
| P/AUM (%) | 0.9 | 0.8 | 0.7 | 0.5 | 0.5 | 0.4 | 0.3 | 0.3 |
| P/EV (x) | 6.0 | 4.9 | 4.1 | 3.4 | 2.9 | 2.6 | 2.2 | 1.9 |
| P/EPS (x) | 73.5 | 60.1 | 43.7 | 45.9 | 40.6 | 38.0 | 30.5 | 25.6 |

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



NOTES



| Explanation of Investment Rating | | |
|----------------------------------|--|--|
| Investment Rating | Expected return (over 12-month) | |
| BUY | >=15% | |
| SELL | < - 10% | |
| NEUTRAL | > - 10 % to 15% | |
| UNDER REVIEW | Rating may undergo a change | |
| NOT RATED | We have forward looking estimates for the stock but we refrain from assigning recommendation | |

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at https://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- . MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- . Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

| Disclosure of Interest Statement | HDFC Life Insurance | |
|----------------------------------|---------------------|--|
| Analyst ownership of the stock | No | |
| Analyst ownership of the stock | 110 | |

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act

15 October 2025



and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore .Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell

| Offevarioe Neuressai Celi. | | | | | | | |
|----------------------------|-----------------------------|------------------------------|--|--|--|--|--|
| Contact Person | Contact No. | Email ID | | | | | |
| Ms. Hemangi Date | 022 40548000 / 022 67490600 | query@motilaloswal.com | | | | | |
| Ms. Kumud Upadhyay | 022 40548082 | servicehead@motilaloswal.com | | | | | |
| Mr. Aiay Menon | 022 40548083 | am@motilaloswal.com | | | | | |

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.

15 October 2025